Last reviewed · How we verify
RA3-RACM7
RA3-RACM7 is a Small molecule drug developed by Buddhist Tzu Chi General Hospital. It is currently FDA-approved. Also known as: Pariet x 10 days., Hiconcil x 10 days., Klarid x 7 days., Flagyl x 7 days..
RA3-RACM7 is being studied as a treatment for Helicobacter Pylori Infection, according to ClinicalTrials.gov. The treatment involves a combination of RA3 and RACM7, although the exact mechanism of action is not specified in the available information.
At a glance
| Generic name | RA3-RACM7 |
|---|---|
| Also known as | Pariet x 10 days., Hiconcil x 10 days., Klarid x 7 days., Flagyl x 7 days. |
| Sponsor | Buddhist Tzu Chi General Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RA3-RACM7 CI brief — competitive landscape report
- RA3-RACM7 updates RSS · CI watch RSS
- Buddhist Tzu Chi General Hospital portfolio CI
Frequently asked questions about RA3-RACM7
What is RA3-RACM7?
Who makes RA3-RACM7?
Is RA3-RACM7 also known as anything else?
What development phase is RA3-RACM7 in?
Related
- Manufacturer: Buddhist Tzu Chi General Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Pariet x 10 days., Hiconcil x 10 days., Klarid x 7 days., Flagyl x 7 days.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing